Fate Therapeutics (FATE) Tops Q2 EPS by 2c
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Fate Therapeutics (NASDAQ: FATE) reported Q2 EPS of ($0.29), $0.02 better than the analyst estimate of ($0.31). Revenue for the quarter came in at $1.03 million versus the consensus estimate of $1.02 million.
For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mondelez Int'l (MDLZ) Tops Q3 EPS by 9c, Offers Outlook
- Franklin Resources (BEN) Tops Q4 EPS by 13c
- AVX Corp. (AVX) Misses Q2 EPS by 2c
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!